We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Inks Deal With Scorpion Therapeutics to Target ‘Undruggable’ Cancers
AstraZeneca Inks Deal With Scorpion Therapeutics to Target ‘Undruggable’ Cancers
AstraZeneca has signed a collaboration deal with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, the so-called “undruggable” targets.